Trial results for the HistoSonics Investigational System for Kidney Cancer were posted on ClinicalTrials.gov on 2025-12-02, reporting 100.0% technical success in treating primary solid renal tumors.
Background
Kidney cancer, also known as renal cancer, involves the uncontrolled growth of abnormal cells in the kidney. Treatment options typically include surgery, radiation therapy, chemotherapy, and targeted therapies. While surgical removal of the tumor remains a primary approach, less invasive techniques are continuously being explored to reduce patient morbidity and recovery times. The HistoSonics Investigational System utilizes histotripsy, a non-invasive technology, to mechanically destroy target tissue. This trial aimed to evaluate the technical success and safety profile of this system for treating primary solid renal tumors, offering a potential alternative for patients.
Trial design
This completed study, designated as Phase NA, enrolled 20 participants to investigate conditions including Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, and Tumor, Benign. The trial evaluated the HistoSonics Investigational System for the treatment of primary solid renal tumors. The primary objective was to assess the technical success and safety profile of the system.
Key results
The trial reported two key measurements for the HistoSonics Investigational System:
- For Primary Effectiveness: Technical Success, the system achieved 100.0% percentage of tumors.
- For Primary Safety: Freedom From Index Procedure Related Major Complications, 90.9% percentage of participants were observed.
What this means
The posted results indicate a high rate of technical success for the HistoSonics Investigational System in treating primary solid renal tumors, with 100.0% of tumors successfully treated. The safety profile also appears favorable, with 90.9% of participants experiencing freedom from index procedure-related major complications. These findings suggest that histotripsy could be a promising non-invasive option for kidney cancer. As this was a completed study with 20 participants, further research may be needed to confirm these outcomes in larger populations and diverse clinical settings.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05432232, titled "The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy", were posted on 2025-12-02 on clinicaltrials.gov.